Skip to content

Cancer Dyspnea Relief Trial

Cancer Dyspnea Relief Trial - CDR Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005760
Enrollment
100
Registered
2011-07-01
Start date
2012-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspnea in cancer patient

Interventions

immediate release oxycodone immediate release morphine

Sponsors

Osaka University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) written consent (2) inpatient or outpatient (3) localy advanced or metastatic disease (4)prescribed SR oxycodone 20-200mg/day for regular analgesics (5) clinically clear consiousness (6) intensity of dyspnea in rest more than 3 in NRS (7) SpO2 > 90%, with supplimental oxygen if needed (8) ECOG PS 0-3

Exclusion criteria

Exclusion criteria: (1) anemia is a cause of dyspnea (2) acute respiratory failure (3) decompensated heart failure (4) impairment of liver function: 5 times higher than upper normal value of AST or ALT, or total bilirubin > 2mg/dl (5) renal insufficiency : twice higher than upper normal value of Cr (6) bacterial enteritis (7) unstable pain: more than 5 in NRS(0-10) and plan to increase opioid within next 24hr (8) expected prognosis is less than 1 month (9) hypersensitivity to opium alkaloid (10) opioid rescue use for pain within 9 hour before taking investigational drug (11) opioid analgesic use for any symptoms other than pain within 24 hour before taking investigational drug (12) history of taking opioid rescue for dyspnea (13) prescribed codein, morphine, fentanyl, tramadol, or buprenorphine as regular medication (14) those who is considered not to be qualified for this trial by primary responsible doctor

Design outcomes

Primary

MeasureTime frame
mean change in intensity of dyspnea evaluated by NRS at 60 minutes after taking investigational drug in each group.

Secondary

MeasureTime frame
(1) mean change in intensity of dyspnea evaluated by NRS at 120 minutes after taking investigational drug in each group. (2)the rate of the patietnts with more than 1 reduction in dyspnea intensity evaluated by NRS at 60 and 120 minutes after taking investigational drug in each group.

Countries

Japan

Contacts

Public ContactTakashi Yamaguchi

Kobe University hospital Department of Palliative Medicine

ikagoro@pop06.odn.ne.jp078-382-6531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026